US Army Creating Vaccine That Fights All COVID And SARS Variants

Photo by AHMAD GHARABLI/AFP via Getty Images

Daily Caller News Foundation logo
Sebastian Hughes Politics Reporter
Font Size:

Scientists at the Walter Reed Army Institute of Research are expected to announce that they’ve created a vaccine that will be effective against all COVID-19 and SARS variants, including Omicron, in the coming weeks, Defense One reported.

The Army lab received its first DNA sequencing of the COVID-19 virus in early 2020 and spent the next two years working on it, Defense One reported. Walter Reed’s infectious diseases branch soon chose to focus on inventing a vaccine that would prove effective against all variants, not just the original.

The vaccine lab eventually completed animal testing in early 2021 with positive results, and Phase 1 human trials finished in December. The human trials tested the vaccine against the Omicron variant and also had positive results, Dr. Kayvon Modjarrad, director of Walter Reed’s infectious diseases branch, told Defense One.

This photo taken 09 July 2001 shows the main entra

The main entrance of Walter Reed Army Medical Center in Washington, DC on July 9, 2001. (Photo by EMILIE SOMMER/AFP via Getty Images)

Walter Reed’s Spike Ferritin Nanoparticle COVID-19 vaccine (SpFN) uses a soccer ball-shaped protein with 24 faces, which allows scientists to attach spikes of multiple coronavirus strains on different faces of the protein, Defense One reported.

“It’s very exciting to get to this point for our entire team and I think for the entire Army as well,” Modjarrad said. (RELATED: Biden Says COVID Rapid Test Shortage Not His Administration’s Fault Because Latest Variant Was Such A Surprise)

“With Omicron, there’s no way really to escape this virus. You’re not going to be able to avoid it,” he added. “So I think pretty soon either the whole world will be vaccinated or have been infected.”

The next step in the process will be to see how the vaccine interacts with people who have already been vaccinated or contracted the virus, Defense One reported.

“We need to evaluate it in the real-world setting and try to understand how does the vaccine perform in much larger numbers of individuals who have already been vaccinated with something else initially…or already been sick,” Modjarrad said.

All content created by the Daily Caller News Foundation, an independent and nonpartisan newswire service, is available without charge to any legitimate news publisher that can provide a large audience. All republished articles must include our logo, our reporter’s byline and their DCNF affiliation. For any questions about our guidelines or partnering with us, please contact